Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15333587 | 0.90 | CYP3A4 (0.39) | CYP3A4L3MBTL1PSIP1 | |
| SCHEMBL15333588 | 0.90 | CYP3A4 (0.39) | CYP3A4L3MBTL1PSIP1 | |
| SCHEMBL15526296 | 0.89 | CYP3A4 (0.38) | CYP3A4TDP1L3MBTL1PSIP1 | |
| SCHEMBL15342328 | 0.89 | CYP3A4 (0.38) | CYP3A4TDP1L3MBTL1PSIP1 | |
| SCHEMBL15331460 | 0.88 | CYP3A4 (0.48) | CYP3A4NPC1RAB9APSIP1 | |
| SCHEMBL15342305 | 0.86 | CYP3A4 (0.34) | CYP3A4NPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL15332755 | 0.85 | NPC1 (0.38) | CYP3A4NPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL15332754 | 0.85 | NPC1 (0.38) | CYP3A4NPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL15332750 | 0.85 | NPC1 (0.38) | CYP3A4NPC1RAB9ATDP1L3MBTL1 | |
| SCHEMBL31114919 | 0.83 | MAPT (0.35) | CYP3A4TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | CYP3A4 272/4885NPC1 6/4885RAB9A 181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.